Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 270,920
  • Shares Outstanding, K 17,558
  • Annual Sales, $ 116,880 K
  • Annual Income, $ -25,090 K
  • 60-Month Beta 0.94
  • Price/Sales 2.32
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RIGL with:

Options Overview Details

View History
  • Implied Volatility 7.41% ( -89.83%)
  • Historical Volatility 61.27%
  • IV Percentile 1%
  • IV Rank 0.00%
  • IV High 307.91% on 01/09/24
  • IV Low 7.41% on 10/11/24
  • Put/Call Vol Ratio 1.50
  • Today's Volume 25
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 1.76
  • Today's Open Interest 7,343
  • Open Int (30-Day) 9,521

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.01
  • Number of Estimates 4
  • High Estimate 0.25
  • Low Estimate -0.21
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +103.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.76 +20.92%
on 09/12/24
17.18 -10.21%
on 09/27/24
+2.46 (+18.97%)
since 09/11/24
3-Month
8.61 +79.21%
on 08/05/24
17.18 -10.21%
on 09/27/24
+5.81 (+60.40%)
since 07/11/24
52-Week
7.12 +116.71%
on 10/25/23
17.30 -10.81%
on 03/06/24
+5.43 (+54.30%)
since 10/11/23

Most Recent Stories

More News
Rigel: Q2 Earnings Snapshot

Rigel: Q2 Earnings Snapshot

RIGL : 15.43 (+1.31%)
Rigel: Q1 Earnings Snapshot

Rigel: Q1 Earnings Snapshot

RIGL : 15.43 (+1.31%)
Rigel: Q3 Earnings Snapshot

Rigel: Q3 Earnings Snapshot

RIGL : 15.43 (+1.31%)
Rigel Announces Presentation at the Upcoming IDWeek 2023

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical...

RIGL : 15.43 (+1.31%)
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...

RIGL : 15.43 (+1.31%)
Rigel to Present at the 2023 Cantor Global Healthcare Conference

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company...

RIGL : 15.43 (+1.31%)
Rigel to Participate in Upcoming September Investor Conferences

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean...

RIGL : 15.43 (+1.31%)
Rigel: Q2 Earnings Snapshot

Rigel: Q2 Earnings Snapshot

RIGL : 15.43 (+1.31%)
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2023, including sales of...

RIGL : 15.43 (+1.31%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....

RIGL : 15.43 (+1.31%)

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 16.08
2nd Resistance Point 15.77
1st Resistance Point 15.60
Last Price 15.43
1st Support Level 15.11
2nd Support Level 14.80
3rd Support Level 14.63

See More

52-Week High 17.30
Last Price 15.43
Fibonacci 61.8% 13.41
Fibonacci 50% 12.21
Fibonacci 38.2% 11.01
52-Week Low 7.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar